Dr Samar Hasan

Hasan, S. B., Smith, S. P., Brain, A., Mohd Mustapa, M. F., Cheung, S. T., Ingram, J. R. and de Berker, D. A. R. 2021. British Association of Dermatologists (BAD) national clinical audit on the management of Hidradenitis Suppurativa (HS) in the UK. Clinical and Experimental Dermatology 46(6), pp. 1023-1027. (10.1111/ced.14598)

Hasan, S. and Ingram, J. 2020. What has changed in the UK management of hidradenitis suppurativa from 2014 to 2019?. British Journal of Dermatology 183(5), pp. 973-975. (10.1111/bjd.19302)
Hasan, S., Ali, F. and Ingram, J. 2020. Cholinergic pruritus responding to Omalizumab. Clinical and Experimental Dermatology 45(2), pp. 264-266. (10.1111/ced.14052)

Hasan, S. B. et al. 2024. Feasibility of daily pain measurement using text messages in Hidradenitis Suppurativa clinical trials; Data from THESEUS study. British Journal of Dermatology 190(5), pp. 775-777., article number: ljae057. (10.1093/bjd/ljae057)
James, J. F. et al. 2023. Demographic gaps and requirements for participation: A systematic review of clinical trial designs in Hidradenitis Suppurativa. Dermatology 239, pp. 45-51. (10.1159/000526069)
Hasan, S., Gendra, R., James, J., Morris, D., Orenstein, L. and Ingram, J. 2022. Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: A scoping review to inform pain measurement in hidradenitis suppurativa. British Journal of Dermatology 187(6), pp. 846-854. (10.1111/bjd.21821)
Hasan, S. B., Smith, S. P., Brain, A., Mohd Mustapa, M. F., Cheung, S. T., Ingram, J. R. and de Berker, D. A. R. 2021. British Association of Dermatologists (BAD) national clinical audit on the management of Hidradenitis Suppurativa (HS) in the UK. Clinical and Experimental Dermatology 46(6), pp. 1023-1027. (10.1111/ced.14598)
Hasan, S. and Ingram, J. 2020. What has changed in the UK management of hidradenitis suppurativa from 2014 to 2019?. British Journal of Dermatology 183(5), pp. 973-975. (10.1111/bjd.19302)
Hasan, S., Ali, F. and Ingram, J. 2020. Cholinergic pruritus responding to Omalizumab. Clinical and Experimental Dermatology 45(2), pp. 264-266. (10.1111/ced.14052)

Publication